New drug cocktail shows promise for Hard-to-Treat myeloma
NCT ID NCT04850599
First seen Jan 05, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in about 5 adults with multiple myeloma that has come back or stopped responding to treatment. The goal is to see how well the drugs work together to shrink or control the cancer. This is not a cure, but aims to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.